

# Stefan Siebert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3258719/publications.pdf>

Version: 2024-02-01

90  
papers

3,445  
citations

159358

30  
h-index

155451

55  
g-index

94  
all docs

94  
docs citations

94  
times ranked

5468  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. <i>Pharmacological Reviews</i> , 2015, 67, 280-309.	7.1	266
2	Rheumatoid arthritis and depression: an inflammatory perspective. <i>Lancet Psychiatry</i> , 2019, 6, 164-173.	3.7	238
3	JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 143-154.	0.9	221
4	Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. <i>Clinical and Experimental Immunology</i> , 2014, 176, 1-10.	1.1	180
5	Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases. <i>Annual Review of Medicine</i> , 2016, 67, 337-353.	5.0	159
6	Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. <i>PLoS Medicine</i> , 2019, 16, e1002739.	3.9	144
7	The role of the immune system in kidney disease. <i>Clinical and Experimental Immunology</i> , 2018, 192, 142-150.	1.1	131
8	Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. <i>Nature Reviews Rheumatology</i> , 2019, 15, 461-474.	3.5	95
9	A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1437-1449.	2.9	77
10	Why did IL-23/p19 inhibition fail in AS: a tale of tissues, trials or translation?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1015-1018.	0.5	77
11	JAK inhibitors and infections risk: focus on herpes zoster. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093605.	1.2	72
12	No Increased Rate of Acute Myocardial Infarction or Stroke Among Patients with Ankylosing Spondylitis: A Retrospective Cohort Study Using Routine Data. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 140-145.	1.6	68
13	Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0154515.	1.1	64
14	Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia. <i>Arthritis and Rheumatology</i> , 2017, 69, 2144-2150.	2.9	59
15	Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. <i>Arthritis and Rheumatism</i> , 2005, 52, 1287-1292.	6.7	58
16	Qualitative research within trials: developing a standard operating procedure for a clinical trials unit. <i>Trials</i> , 2013, 14, 54.	0.7	56
17	Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502,649 UK Biobank participants. <i>RMD Open</i> , 2016, 2, e000267.	1.8	55
18	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. <i>British Journal of Dermatology</i> , 2020, 182, 130-137.	1.4	52

#	ARTICLE	IF	CITATIONS
19	The effect of exercise on cytokines: implications for musculoskeletal health: a narrative review. BMC Sports Science, Medicine and Rehabilitation, 2022, 14, 5.	0.7	51
20	Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthritis. BMC Musculoskeletal Disorders, 2008, 9, 4.	0.8	49
21	Involving service users in trials: developing a standard operating procedure. Trials, 2013, 14, 219.	0.7	49
22	The effect of physical activity and motivation on function in ankylosing spondylitis: A cohort study. Seminars in Arthritis and Rheumatism, 2013, 42, 619-626.	1.6	48
23	Fatigue in Ankylosing Spondylitis: Treatment Should Focus on Pain Management. Seminars in Arthritis and Rheumatism, 2013, 42, 361-367.	1.6	48
24	Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 2290-2294.	1.0	48
25	Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF- $\kappa$ B activation due to decreased surface expression. FEBS Letters, 2005, 579, 5193-5198.	1.3	46
26	Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology, 2019, 58, 1746-1754.	0.9	44
27	The information needs of people living with ankylosing spondylitis: a questionnaire survey. BMC Musculoskeletal Disorders, 2012, 13, 243.	0.8	42
28	BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 Td	0.9	41
29	Treatment strategies in axial spondyloarthritis: what, when and how?. Rheumatology, 2020, 59, iv79-iv89.	0.9	41
30	The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data. PLoS ONE, 2015, 10, e0126105.	1.1	36
31	Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation. Rheumatology, 2016, 55, 120-132.	0.9	32
32	Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Scientific Reports, 2017, 7, 40473.	1.6	32
33	Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy. Rheumatology and Therapy, 2019, 6, 165-177.	1.1	32
34	Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features. RMD Open, 2020, 6, e001376.	1.8	31
35	Cytokine Production by Hepatic Anaplastic Large-Cell Lymphoma Presenting as a Rheumatic Syndrome. Seminars in Arthritis and Rheumatism, 2007, 37, 63-67.	1.6	30
36	Frequency and characteristics of disease flares in ankylosing spondylitis. Rheumatology, 2010, 49, 929-932.	0.9	30

#	ARTICLE	IF	CITATIONS
37	Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods. <i>Value in Health</i> , 2015, 18, 425-431.	0.1	30
38	Brief Report: Predicting Functional Disability: One-Year Results From the Scottish Early Rheumatoid Arthritis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2016, 68, 1596-1602.	2.9	29
39	Physical activity and sedentary behaviour and their associations with clinical measures in axial spondyloarthritis. <i>Rheumatology International</i> , 2020, 40, 375-381.	1.5	28
40	Services for spondyloarthritis: a survey of patients and rheumatologists. <i>Rheumatology</i> , 2018, 57, 987-996.	0.9	27
41	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. <i>Rheumatology</i> , 2018, 57, 1982-1990.	0.9	26
42	Association of sarcopenia with incident osteoporosis: a prospective study of 168,682 UK biobank participants. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1179-1188.	2.9	26
43	Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 1556-1562.	0.9	25
44	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e337-e346.	2.2	24
45	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 461.	0.8	22
46	Level of adherence to prescribed exercise in spondyloarthritis and factors affecting this adherence: a systematic review. <i>Rheumatology International</i> , 2019, 39, 187-201.	1.5	22
47	Patient perspectives of managing fatigue in Ankylosing Spondylitis, and views on potential interventions: a qualitative study. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 163.	0.8	21
48	Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2019, 46, 701-709.	1.0	21
49	Patterns of multimorbidity and their effects on adverse outcomes in rheumatoid arthritis: a study of 5658 UK Biobank participants. <i>BMJ Open</i> , 2020, 10, e038829.	0.8	20
50	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. <i>RMD Open</i> , 2021, 7, e001679.	1.8	19
51	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 823-830.	0.5	18
52	Severe flare as a predictor of poor outcome in ankylosing spondylitis: a cohort study using questionnaire and routine data linkage. <i>Rheumatology</i> , 2015, 54, 1563-1572.	0.9	16
53	Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank. <i>Rheumatology</i> , 2019, 58, 2137-2142.	0.9	16
54	Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition. <i>Medicine (United States)</i> , 2020, 99, e20458.	0.4	16

#	ARTICLE	IF	CITATIONS
55	Examining the Relationship Between Rheumatoid Arthritis, Multimorbidity, and Adverse Health-Related Outcomes: A Systematic Review. <i>Arthritis Care and Research</i> , 2022, 74, 1500-1512.	1.5	16
56	Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study. <i>Rheumatology</i> , 2022, 61, 1026-1034.	0.9	15
57	Proptosis can be the presenting feature of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 908-909.	0.5	14
58	Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). <i>Rheumatology</i> , 2007, 47, 228-229.	0.9	14
59	The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 349-356.	2.0	14
60	Responsiveness of Serum C-reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2019, 71, 1660-1669.	2.9	13
61	Does Age Matter in Psoriatic Arthritis? A Narrative Review. <i>Journal of Rheumatology</i> , 2022, 49, 1085-1091.	1.0	13
62	Protocol for a population-based Ankylosing Spondylitis (PAS) cohort in Wales. <i>BMC Musculoskeletal Disorders</i> , 2010, 11, 197.	0.8	12
63	Web-based physiotherapy for people with axial spondyloarthritis (WEBPASS) – a study protocol. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 360.	0.8	12
64	Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. <i>RMD Open</i> , 2020, 6, e001206.	1.8	11
65	HERALD (Health Economics using Routine Anonymised Linked Data). <i>BMC Medical Informatics and Decision Making</i> , 2012, 12, 24.	1.5	10
66	AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). <i>BMC Rheumatology</i> , 2019, 3, 19.	0.6	10
67	Protocol for a multicentre randomised controlled parallel-group trial to compare the effectiveness of remotely delivered cognitive-behavioural and graded exercise interventions with usual care alone to lessen the impact of fatigue in inflammatory rheumatic diseases (LIFT). <i>BMJ Open</i> , 2019, 9, e026793.	0.8	9
68	The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 941-952.	1.5	9
69	Frailty in rheumatoid arthritis and its relationship with disease activity, hospitalisation and mortality: a longitudinal analysis of the Scottish Early Rheumatoid Arthritis cohort and UK Biobank. <i>RMD Open</i> , 2022, 8, e002111.	1.8	9
70	Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. <i>FEBS Letters</i> , 2004, 570, 138-142.	1.3	7
71	Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity – a cross-sectional study. <i>Rheumatology</i> , 2021, 60, 1858-1862.	0.9	7
72	Examining the relationship between rheumatoid arthritis, multimorbidity and adverse health-related outcomes: A systematic review protocol. <i>Journal of Comorbidity</i> , 2020, 10, 2235042X2090665.	3.9	6

#	ARTICLE	IF	CITATIONS
73	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. <i>Rheumatology</i> , 2022, 61, e255-e266.	0.9	6
74	Editorial: Choosing New Targets for Rheumatoid Arthritis Therapeutics: Too Interesting to Fail?. <i>Arthritis and Rheumatology</i> , 2017, 69, 1131-1134.	2.9	4
75	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021, 60, 1588-1592.	0.9	4
76	Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 281.	1.0	3
77	T cells and cytokines in inflamed psoriatic skin. Who's in charge?. <i>Immunology</i> , 2020, 160, 311-312.	2.0	3
78	Correspondence on "No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related "physician-reported spondylitis". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e185-e185.	0.5	3
79	Clinical images: Brown's syndrome: an unusual case of diplopia in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2460-2460.	6.7	2
80	The extending scope of kinase inhibition in immune diseases. <i>Lancet, The</i> , 2018, 392, 2328-2331.	6.3	2
81	Frailty in people with rheumatoid arthritis: a systematic review of observational studies. <i>Wellcome Open Research</i> , 0, 6, 244.	0.9	2
82	Major flares as a diagnostic and prognostic measure when assessing ankylosing spondylitis severity. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 399-401.	0.3	1
83	216. "The Work-Related Costs of Ankylosing Spondylitis in a UK Cohort. <i>Rheumatology</i> , 2014, 53, i140-i141.	0.9	1
84	TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis. <i>Trials</i> , 2021, 22, 433.	0.7	1
85	Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa063.	0.3	1
86	HERALD (Health Economics using Routine Anonymised Linked Data). <i>Trials</i> , 2011, 12, .	0.7	0
87	BRITSpA at five. <i>Rheumatology</i> , 2020, 59, 699-701.	0.9	0
88	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa043.	0.3	0
89	Estimating Cardiovascular Impacts of Drugs for Psoriatic Disease: A Long Way to Go. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2322-2325.	0.3	0
90	Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, , jrheum.211337.	1.0	0